LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion

Author： de Jong Igle Jan   Eaton Alan   Bladou Franck  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.23, Iss.5, 2007-05, pp. : 1077-1080

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of Surgical and Medical Castration on Serum Testosterone Level in Prostate Cancer Patients

By  

Urologia Internationalis, Vol. 82, Iss. 3, 2009-05 ,pp. : 249-255

Karger

Access to resources Recommend Favorite

Climacteric-Like Disorders in Prostate Cancer Patients Treated With LHRH Agonists

By Nishimura K.   Yamaguchi Y.   Yamanaka M.   Ichikawa Y.   Nagano S.  

Archives of Andrology, Vol. 51, Iss. 1, 2005-01 ,pp. : 41-48

Informa Healthcare

Access to resources Recommend Favorite

Quality of Life in Patients with Prostate Cancer Treated with LH-RH Agonists

By  

Current Urology, Vol. 2, Iss. 1, 2008-08 ,pp. : 30-35

Karger

Access to resources Recommend Favorite

Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl

By  

Current Urology, Vol. 9, Iss. 1, 2015-0 ,pp. : 31-35

Karger

Access to resources Recommend Favorite

Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer

By  

Urologia Internationalis, Vol. 77, Iss. 2, 2006-08 ,pp. : 135-138

Karger

Access to resources Recommend Favorite